Report Id: SNS/HC/1763 | June 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Digital Pathology Market size was estimated at USD 937.3 million annually by 2021, and is expected to reach USD 1544.9 million by 2028, and improve to a CAGR of 7.4% over the estimated 2022-2028 period.
Digital pathology is a part of pathology that spotlights on information the executives in view of data produced from advanced created test slides. Advanced pathology utilizes virtual microscopy with the assistance of PC based innovation. Despite the fact that the basic visual acuity has not changed much, digital pathology has resulted in significant improvements in pathology laboratory efficiency, workflow, and revenue. Digital pathology enables the user to convert glass slides into digital slides that can be manipulated, shared, viewed, and analyzed on a computer monitor. Automatic image analysis tools can also be used to help define and measure biomarker expression within tissue categories.
Primary diagnostics, consultation and diagnosis, internal diagnostics, medical and resident student training, manual and semi-quantitative immunohistochemistry (IHC) reviews, clinical research, diagnostic support support, peer review, and tumor boards are all examples of digital care applications. pathology. Advanced scanning of glass slides, analyzing the value of all slide images, real-time web-based consultations with experienced pathologists, and secure storage of pathology data are some of the Life Science applications. With specialized educational support, muscle-based research, drug development, and human pathology work around the world, digital pathology is rapidly gaining ground as a proven and important technology.
Increased acceptance of digital pathology to improve laboratory efficiency
Rising Access to Electronic Health Records.
Cost Savings Associated with the Use of Digital Pathology
The high cost of digital pathology programs
Introduction of affordable scanners for independent pathology processes
Lack of trained pathologists
IMPACT OF COVID-19
The outbreak of COVID-19 is expected to have a positive impact on the growth of the digital pathology market globally. U.S. Center for Devices and Radiological Health. The FDA has issued a mandatory policy for remote digital pathology devices, targeted at pathologists, clinical laboratories, and drug control staff. Therefore, the increase in chronic diseases has increased the use of digital diagnostic pathology systems, which are expected to advance the digital pathology market during forecasting.
Therefore, new innovations by key players and an increase in the number of product approvals encourage market growth. However, the high costs associated with digital pathology systems are expected to hamper market growth during forecasting.
The device component includes scanner and slide management systems. The growing acceptance of educational research activities and improved solutions are the key to component growth. This technology is expected to see significant gains in the forecast period due to advances in enlargement and scanning slides on the Z-axis, which is provided by the full slide image. In addition, accurate user connections and high bandwidth connections are expected to increase your usage values. Major players are constantly introducing technological advances in digital pathology scanners.
The global digital pathology market is divided into human pathology and veterinary pathology. The human pathology segment had the largest share of the digital pathology market in 2021. This is due to the growing number of cancer research activities and the growing collaboration between research institutes, universities, and research centers.
The digital pathology market is divided into drug discovery, diagnosis, training and education. The drug discovery segment had the largest share in the digital pathology market by 2021. The increase in R&D costs is driven by the need for more pre-clinical and clinical studies conducted during drug discovery and the development process is a major factor responsible for market growth.
By End Use
The worldwide Digital pathology market is separated into drug and biotechnology organizations, medical clinics and reference labs, and instructive and research establishments. Part of the drug and biotechnology organizations turned into the biggest investor in the advanced pathology market by 2020. A major contribution to this category can be attributed to the increasing use of digital pathology in drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular testing, and individual drug development.
Some of the major key players are as follows: 3DHISTECH Ltd., F. Hoffmann-La Roche Ltd., Hamamatsu Photonics, Inc., Huron Technologies International, Inc., Inspirata, Inc., Koninklijke Philips N.V., Leica Biosystems (Danaher), Mikroscan Technologies, Olympus Corporation, Visiopharm A/S, and other players.
Information Management Software
Image Analysis Software
Training & Education
By End User
Pharmaceutical & Biotechnology Companies
Hospitals and Reference Laboratories
Academic & Research Institutes
North America ruled the digital pathology market by 2021, and is supposed to keep on overwhelming the gauge period, because of rising quantities of various sorts of disease cases, the presence of central participants, the improvement of the medical care industry, and the accessibility of development. digital pathology systems in the region. However, Asia-Pacific is expected to register a very high CAGR of 7.4% from 2022 to 2028, due to an increase in the spread of chronic diseases, and the development of health care infrastructure.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 937.3 Million|
|Market Size by 2028||US$ 1544.9 Million|
|CAGR||CAGR of 7.4% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product (Scanners (Brightfield, Other Scanners), Software (Integrated Software, Standalone Software, Information Management Software, Image Analysis Software), Storage Systems), Type (Human Pathology, Veterinary Pathology)
• By Application (Drug Discovery, Disease Diagnosis, Training & Education)
• By End User (Pharmaceutical & Biotechnology Companies, Hospitals and Reference Laboratories, Academic & Research Institutes)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||3DHISTECH Ltd., F. Hoffmann-La Roche Ltd., Hamamatsu Photonics, Inc., Huron Technologies International, Inc., Inspirata, Inc., Koninklijke Philips N.V., Leica Biosystems (Danaher), Mikroscan Technologies, Olympus Corporation, Visiopharm A/S, and other players.|
|DRIVERS||• Increased acceptance of digital pathology to improve laboratory efficiency
• Rising Access to Electronic Health Records.
• Cost Savings Associated with the Use of Digital Pathology
|RESTRAINTS||• The high cost of digital pathology programs|
Frequently Asked Questions (FAQ) :
Human Pathology, and Veterinary Pathology are the sub segment of by type of Dental X-Ray Market.
North America ruled the digital pathology market.
Digital Pathology Market is divided into four segments and they are By Product, By Type, By Application, and by End User
The high cost of digital pathology programs are the restraints of the Digital Pathology market.
Digital Pathology market is expected grow at a CAGR of 7.4% over the forecast period 2022-2028.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Digital Pathology Market Segmentation, By Product
8.1.2 Other Scanners
8.2.1 Integrated Software
8.2.2 Standalone Software
8.2.3 Information Management Software
8.2.4 Image Analysis Software
8.3 Storage Systems
9. Digital Pathology Market Segmentation, By Type
9.1 Human Pathology
9.2 Veterinary Pathology
10. Digital Pathology Market Segmentation, By Application
10.4 Drug Discovery
10.5 Disease Diagnosis
10.6 Training & Education
11. Digital Pathology Market Segmentation, By End User
11.1 Pharmaceutical & Biotechnology Companies
11.2 Hospitals and Reference Laboratories
11.3 Academic & Research Institutes
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13 Company Profiles
13.1 3DHISTECH Ltd
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 F. Hoffmann-La Roche Ltd.
13.3 Hamamatsu Photonics, Inc.
13.4 Huron Technologies International, Inc.
13.5 Inspirata, Inc.
13.6 Koninklijke Philips N.V.
13.7 Leica Biosystems (Danaher)
13.8 Mikroscan Technologies
13.9 Olympus Corporation
13.10 Visiopharm A/S.
14 Competitive Landscape
14.1 Competitive Benchmark
14.2 Market Share analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.